Huiqing Yu

A prognostic model using the neutrophil-albumin ratio and PG-SGA to predict overall survival in advanced palliative lung cancer

Haoyang Cao, Changyan Feng, Huiqing Yu, 2022, BMC Palliative Care.

Altered brain functional activity and connectivity in bone metastasis pain of lung cancer patients: A preliminary resting-state fMRI study

Daihong Liu, Jiuquan Zhang, Liejun Yang, 2022, Frontiers in Neurology.

Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study

T. Wang, Yanqiu Zhao, Jianying Zhou, 2023, BMC Medicine.

Early Palliative Care in Patients With Non–Small-Cell Lung Cancer: A Randomized Controlled Trial in Southwest China

Huiqing Yu, Liejun Yang, Shihong Liu, 2022, The American journal of hospice & palliative care.

Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studies.

T. Wang, D. Zhong, Yanqiu Zhao, 2023, Lung cancer.

Ef fi cacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/ Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study

T. Wang, D. Zhong, Yanqiu Zhao, 2022 .

HE4 as a biomarker for diagnosis of lung cancer

Jia-Xi Tang, Wei-Qi Nian, Huiqing Yu, 2019, Medicine.

Safety, Efficacy and Pharmacokinetics of Rezivertinib (BPI-7711) in Advanced Non-Small Cell Lung Cancer Patients with EGFR T790M Mutation: a Phase 1 Dose-Escalation and Dose-Expansion Study.

Yanqiu Zhao, Y. Shu, Gong-yan Chen, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

JK5G postbiotics attenuate immune-related adverse events in NSCLC patients by regulating gut microbiota: a randomized controlled trial in China

Liling Ma, Liejun Yang, Juan Gong, 2023, Frontiers in oncology.